Differential Changes in the Content of Amino Acid Neurotransmitters in Discrete Regions of the Rat Brain Prior to the Onset and During the Course of Homocysteine-Induced Seizures

1986 ◽  
Vol 46 (5) ◽  
pp. 1582-1592 ◽  
Author(s):  
Ian C. Allen ◽  
Angus Grieve ◽  
Roger Griffiths
Keyword(s):  
Amino Acid ◽  
Rat Brain ◽  
Amino Acid Neurotransmitters

Effect of Three Different Intensities of Infrared Laser Energy on the Levels of Amino Acid Neurotransmitters in the Cortex and Hippocampus of Rat Brain

2008 ◽  
Vol 26 (5) ◽  
pp. 479-488 ◽  
Author(s):  
Nawal Abd El Hay Ahmed ◽  
Nasr Mahmoud Radwan ◽  
Khayria Mansour Ibrahim ◽  
Mona Emam Khedr ◽  
Mona A. El Aziz ◽  
...  
Keyword(s):  
Amino Acid ◽  
Rat Brain ◽  
Laser Energy ◽  
Infrared Laser ◽  
Amino Acid Neurotransmitters

scholarly journals Studies on Aromatic Amino Acid Uptake by Rat Brain in Vivo

1962 ◽  
Vol 237 (3) ◽  
pp. 803-806
Author(s):  
Gordon Guroff ◽  
Sidney Udenfriend
Keyword(s):  
Amino Acid ◽  
Rat Brain ◽  
Aromatic Amino Acid ◽  
Amino Acid Uptake ◽  
Acid Uptake

scholarly journals Emerging Therapeutics Based on the Amino Acid Neurotransmitter System: An Update on the Pharmaceutical Pipeline for Mood Disorders

2021 ◽  
Vol 5 ◽  
pp. 247054702110204
Author(s):  
Julia Hecking ◽  
Pasha A. Davoudian ◽  
Samuel T. Wilkinson
Keyword(s):  
Amino Acid ◽  
Mood Disorders ◽  
Phase Iii ◽  
Public Health Issue ◽  
Complex Nature ◽  
Novel Therapies ◽  
Amino Acid Neurotransmitters ◽  
Neurotransmitter System ◽  
Phase Iii Clinical Trials ◽  
The World

Mood disorders represent a pressing public health issue and significant source of disability throughout the world. The classical monoamine hypothesis, while useful in developing improved understanding and clinical treatments, has not fully captured the complex nature underlying mood disorders. Despite these shortcomings, the monoamine hypothesis continues to dominate the conceptual framework when approaching mood disorders. However, recent advances in basic and clinical research have led to a greater appreciation for the role that amino acid neurotransmitters play in the pathophysiology of mood disorders and as potential targets for novel therapies. In this article we review progress of compounds that focus on these systems. We cover both glutamate-targeting drugs such as: esketamine, AVP-786, REL-1017, AXS-05, rapastinel (GLYX-13), AV-101, NRX-101; as well as GABA-targeting drugs such as: brexanolone (SAGE-547), ganaxolone, zuranolone (SAGE-217), and PRAX-114. We focus the review on phase-II and phase-III clinical trials and evaluate the extant data and progress of these compounds.

Sign in / Sign up

Export Citation Format

Share Document